Publications 2017- 2023

Langley PC. Validating Imaginary Worlds? The AdViSHE Assessment Tool. Inov Pharm.
2017;8(1): No.3

Langley PC. Denkbeeldige Wereld: The New Dutch Guidelines for Economic Evaluations in
Healthcare. Inov Pharm. 2017;8(1): No. 4

Langley PC. Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to
the Pharmaceutical Benefits Advisory Committee (PBAC). Inov Pharm. 2017;8(1): No. 5

Langley PC. HAS Should Not Be NICE: Rejecting Imaginary Worlds in the French Technology
Assessment Guidelines. Inov Pharm. 2017;8(1): No. 8

Langley PC. Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report
of the Institute for Clinical and Economic Review (ICER). Inov Pharm. 2017;8(1): No. 12

Langley PC. Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health
Technology Assessment Model? Inov Pharm. 2017;8(1): No. 13

Langley PC. Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An
Overview of Commentaries in Innovations in Pharmacy from July 2016 to February 2017. Inov
Pharm. 2017;8(1): No. 22

Langley PC. True North: Building Imaginary Worlds with the Revised Canadian (CADTH)
Guidelines for Health Technology Assessment. Inov Pharm. 2017;8(2): No. 9.

Langley PC. Imaginary Worlds and the Institute for Clinical and Economic Review (ICER)
Evidence Report: Targeted Immune Modulators for Rheumatoid Arthritis. Inov Pharm.
2017;8(2): No. 10.

Langley PC. Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9
Inhibitors. Inov Pharm. 2017;8(2): No. 11

Langley PC, Rhee T. The Imaginary Worlds of ISPOR: Modeled Cost-Effectiveness Claims
Published in Value in Health from January 2016 to December 2016. Inov Pharm. 2017;8(2): No.

Langley PC. Potentially Actionable Targets: Evidence Standards for Credible Next Generation
Sequencing Technology Assessment Claims. Inov Pharm. 2017;8(3): No. 9

Langley PC, Rhee TG. More Imaginary Worlds: A Systematic Review of the Status of Modeled
Cost-Effectiveness Claims Published in the Journal of Medical Economics from January 2016 to
December 2016. Inov Pharm. 2017;8(3): No. 13

Langley PC. Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER
Value Assessment Update. Inov Pharm. 2017;8(4): No 7

Langley PC. Transparency, Imaginary Worlds and ICER Value Assessments. Inov Pharm.
2017;8(4): No 11

Langley PC. Another Imaginary World: The ICER Claims for the Long-Term Cost-Effectiveness
and Pricing of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors in Tardive Dyskinesia.
Inov Pharm. 2017;8(4): No 12

Langley PC. Alternative Facts and the ICER Proposed Policy on Access to Imaginary
Pharmacoeconomic Worlds. Inov Pharm. 2018;9(2): No. 10

Langley PC. CVS Health and the imaginary worlds of the Institute for Clinical and Economic
Review (ICER). Inov Pharm. 2018; 9(4):No. 4

Langley PC. Another Rush to Judgement: The Imaginary Worlds of ICER and
Recommendations in Duchenne Muscular Dystrophy. Inov Pharm. 2019;10(3):No. 11

Langley PC. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference
Case Pricing of Transformative Therapies. Inov Pharm. 2019;10(3): No. 17

Langley PC. ICER, ISPOR and QALYs: A Tale of Imaginary Worlds, Inov Pharm. 2019:10(4):
No. 10

Langley PC. Yet another Ersatz World: The ICER Final Evidence Report for Additive
Cardiovascular Therapies. Inov Pharm.2019;10(4); No. 22

Langley PC. More Unnecessary Imaginary Worlds – Part 1: The Institute for Clinical and
Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis,
Inov Pharm. 2020;11(1): No.2

Langley PC. More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on
Modeling Oral Semaglutide for Type 2 Diabetes. InovPharm. 2020;11(1). No. 10

Langley P. Nonsense on Stilts – Part 1: The ICER 2020-2023 value assessment framework for
constructing imaginary worlds. Inov Pharm. 2020;11(1):No. 12

Langley P. More Unnecessary Imaginary Worlds – Part 3: Cystic Fibrosis and the Institute for
Clinical and Economic Review’s Draft Evidence Report. Inov Pharm. 2020;11(1): No. 15

Langley P. More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for
Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease. InovPharm. 2020;11(2):
No. 4

Langley P. Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of
Fundamental Measurement. Inov Pharm. 2020;11(2):No. 8

Langley P. The National Pharmaceutical Council: Endorsing the construction of imaginary
worlds in health technology assessment. Pharmacy. 2020;8(119);doi:10.3390/pharmacy8030119

Langley PC and McKenna SP. Measurement, modeling and QALYs [version 1; peer review: 2
approved] F1000Research 2020, 9:1048

Langley P. The Great I-QALY Disaster. InovPharm. 2020; 11(3): No 7

Langley P. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the
University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in
Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). InovPharm.
2020;11(3): No. 17

Langley P . Value Assessment, Real World Evidence and Fundamental Measurement: Version
3.0 of the Minnesota Formulary Submission Guidelines. InovPharm. 2020;11(4):No. 12

Langley P. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and
Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and
Bladder Cancer Value Claims. InovPharm. 2020;11(4):No. 22

Langley P. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud
Pseudoscience. Inov Pharm. 2021;12(1):No. 5

Langley P. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review:
Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims. InovPharm.
2021;12(1):No. 11

Langley P, McKenna S. Fundamental Measurement and Quality Adjusted Life Years. Value
Health. 2021;24(3):461[letter]

Langley P. McKenna S. Fundamental Measurement: The Need Fulfilment Quality of Life (N-
QOL) Measure. InovPharm.2021;12(2):No. 6

McKenna S, Heaney A, Langley P. Fundamental Outcome Measurement: Selecting Patient
Reported Outcome Instruments and Interpreting the Data they Produce. InovPharm. 2021; 12(2):
No. 17

Langley P. Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the
Institute for Clinical and Economic Review in Health Technology Assessment. InovPharm.
2021; 12(2): No.20

Langley P. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma
Therapies Invented by the Institute for Clinical and Economic Review. Inov Pharm. 2021; 12(3):
No. 6.

Langley P. Abandoning Eugenics and the QALY. Inov Pharm. 2021;12(3): No. 20

Langley P. A Critical Examination of Simulation Pricing and Access Recommendations for
Atopic Dermatitis. Inov Pharm. 2021; 12(3): No. 4

Langley P. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in
Myasthenia Gravis. Inov Pharm.2021; (12)4: No. 10

Langley P. Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value
Claims with CHEERS 22 [version 1; peer review: 2 approved]. F1000Research 2022, 11:248

Langley P. Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.
Inov Pharm. 2022;13(2): No. 1

Langley P. Concerns with Patient Reported Outcome Measurement and Value Claims for
Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy
(SHCM). InovPharm. 2022;13(2): No. 16

Langley P. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of
assumption-driven imaginary value claims in health technology assessment [version 1; peer
review: 3 approved]. F1000Research 2022, 11:993

Langley P. Evidentiary Standards for Patient-Centered Core Impact (PC-CIS) Value Claims.
InovPharm. 2022;13(3): No. 15

Langley P. Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in
Rare Disease. InovPharm. 2023;13(3): No. 9

Langley P. Rasch Measurement and Patient Reported Value Claims: A Primer for Hemophilia.
InovPharm. 2022;13(4): No.16

Langley P. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal
Science and Fundamental Measurement in ICER’S Cost-Effectiveness Assessment of
Fezolinetant for Moderate to Severe Vasomotor Symptoms. InovPharm. 2023;14 (1): Article 9